Clinical Trial Update: Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating 8 weeks of Glecaprevir/Pibrentasvir in treatment-naïve adults with HCV Genotype 1-6 and APRI ≤1; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Glecaprevir/pibrentasvir (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: COMPLETED | Results posted: 2019-09-04